Zoppoli et al. previously found that 23 transcripts including SLFN11 are associated with sensitivity to topoisomerase inhibitors [16]; comparison with genes in Table 2 indicates that 2, 3, 2, 0, and 4 of those 23 genes are associated with sensitization to alkylating agents, anti-metabolites, anti-tumor anti-biotics, microtubule inhibitors, and topoisomerase inhibitors in our analyses, respectively. Here, SLFN11 is linked to neoplasm.